Welcome to our dedicated page for Bausch Health Companies SEC filings (Ticker: BHC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Bausch Health Companies Inc. files periodic reports with the Securities and Exchange Commission as a publicly traded company listed on the New York Stock Exchange under ticker symbol BHC. The company also maintains a listing on the Toronto Stock Exchange. SEC filings provide detailed financial information, risk factors, business segment performance, and management discussion and analysis. Form 10-K annual reports offer comprehensive overviews of operations across the five business segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb.
Quarterly Form 10-Q filings track financial performance throughout the fiscal year, breaking down revenue and profitability by therapeutic area and geographic region. Given the company's significant debt obligations, filings contain detailed disclosures regarding debt structure, maturity schedules, interest expenses, and refinancing activities. Form 8-K current reports disclose material events such as acquisitions, divestitures, executive changes, credit agreement amendments, and significant legal developments. Proxy statements (Form DEF 14A) provide information on corporate governance, executive compensation, board composition, and matters submitted for shareholder votes.
Patent litigation and intellectual property matters affecting key products like XIFAXAN receive disclosure in filings, as generic competition impacts future revenue streams. The company's relationship with Bausch + Lomb, in which it maintains a controlling interest, requires detailed segment reporting and potential disclosure of transactions between the entities. Regulatory compliance, manufacturing quality issues, and FDA enforcement actions would appear in SEC filings when material to investors. Debt covenant compliance, particularly given the company's leveraged capital structure, represents an important area of disclosure.
Investors use SEC filings to monitor trends in prescription volume, pricing dynamics, generic competition, research and development investments, and commercial strategy across therapeutic areas. Financial statements reveal capital allocation decisions, acquisition strategies, and operational efficiency across the diversified pharmaceutical portfolio. Risk factors sections outline threats including patent expirations, regulatory changes, reimbursement pressures, product liability, and competitive dynamics in pharmaceutical markets.
Bausch Health Companies Inc. reports that its subsidiary Bausch + Lomb Corporation has refinanced its term loans by entering into a Fourth Amendment to its Credit and Guaranty Agreement. The amendment establishes a new $2,802,125,000 tranche of term loans maturing on January 15, 2031, with proceeds used to refinance existing term B loans due 2031 and 2028. The new loans amortize at 1.00% per annum, with the first installment due June 30, 2026. The applicable margins are 3.75% per annum for loans tied to term SOFR and 2.75% per annum for loans tied to the alternate base rate, representing reductions of 0.50% and 0.25% per annum compared to the prior tranches. The structure effectively extends the maturity of the earlier 2028 term loans to 2031.
Bausch Health Companies Inc. director John Paulson reported equity-based board compensation and his holdings in a Form 4 filing. On 12/31/2025, he acquired 8,992 restricted share units at a price of $0, issued in lieu of cash compensation for his service on the board for the quarter ending December 31, 2025. Each unit represents a contingent right to receive one common share of Bausch Health with no par value.
Following this transaction, Paulson beneficially owned 360,120 common shares directly. In addition, 73,255,869 common shares were reported as indirectly owned through investment funds managed by Paulson Capital Inc., where he is the controlling person. The filing notes that Paulson may be deemed an indirect beneficial owner of these fund-held securities and that he disclaims beneficial ownership except to the extent of any pecuniary interest.
Bausch Health Companies Inc. director reported receiving an equity-based compensation award for board service. On December 31, 2025, the director acquired 4,586 restricted share units, each representing a contingent right to receive one common share of the company with no par value. These units were issued in lieu of cash compensation for serving on the board for the quarter ending December 31, 2025. Following this award, the director beneficially owned 38,408 common shares on a direct basis.
Bausch Health Companies Inc. reported that one of its directors received equity compensation for board service for the quarter ending December 31, 2025. The director was granted 989 restricted share units, each representing a contingent right to receive one common share with no par value, issued in lieu of cash compensation. After this grant, the reporting person beneficially owned 266,441 common shares, held directly.
Bausch Health Companies Inc. completed previously announced exchange offers, issuing $1.6 billion aggregate principal amount of new 10.00% Senior Secured Notes due 2032 through its indirect wholly owned subsidiary 1261229 B.C. Ltd. These new notes were exchanged for outstanding 4.875% and 11.00% Senior Secured Notes due 2028 under terms described in a confidential exchange offer memorandum.
The new 2032 notes were issued under an existing indenture structure and form a single series with $4.4 billion principal amount of the Issuer’s existing 10.00% Senior Secured Notes due 2032, sharing the same terms except for interest accrual, consideration and temporary securities identifiers. In connection with this issuance, an additional 26,495,472 common shares of Bausch + Lomb Corporation were pledged, bringing the Issuer’s pledged stake to 211,963,893 shares, representing approximately 60% of Bausch + Lomb’s outstanding common shares as of the settlement date. The existing and new notes are secured by a first priority lien on substantially all assets of the Issuer and other guarantors, including this equity stake.
Bausch Health Companies Inc. reported the final results and expiration of its previously announced debt exchange offers. The company had offered holders of its outstanding 4.875% and 11.00% Senior Secured Notes due 2028 the option to exchange into up to $1.6 billion aggregate principal amount of new 10.00% Senior Secured Notes due 2032, to be issued by its indirect wholly owned subsidiary 1261229 B.C. Ltd. These exchanges were conducted under the terms of a confidential exchange offer memorandum dated November 24, 2025, and expired at 5:00 p.m. New York City time on December 23, 2025. Additional details on the final exchange results are provided in a press release attached as an exhibit.
Bausch Health Companies Inc. reported that its subsidiary Bausch + Lomb Corporation has allocated a new
The margins represent a 0.50% per annum reduction versus the existing Third Amendment Term Loans and a 0.25% per annum reduction versus the First Incremental Term Loans. The Replacement Term Loans will mature on
Bausch Health Companies Inc. reported the early results of its previously announced debt exchange offers. The company is offering to exchange its outstanding 4.875% Senior Secured Notes due 2028 and 11.00% Senior Secured Notes due 2028 for up to
Bausch Health Companies Inc. insider filing reports a large share purchase by a major shareholder’s managed funds. On 11/25/2025, investment funds managed by Paulson & Co. acquired 2,500,000 shares of Bausch Health common stock at $6.25 per share. After this transaction, the funds collectively held 73,255,869 shares, reported as indirectly owned "By Managed Funds." The reporting person is identified as a director and 10% owner, and the filing notes that Paulson & Co. and John Paulson may be deemed indirect beneficial owners through their roles with the funds, while formally disclaiming beneficial ownership beyond any pecuniary interest.
Bausch Health Companies Inc. (BHC) has launched exchange offers to swap its outstanding 4.875% and 11.00% Senior Secured Notes due 2028 for up to
Participation is limited to eligible institutional and non‑U.S. holders under U.S. and international securities laws, and acceptances will target a mix of approximately
FAQ
What is the current stock price of Bausch Health Companies (BHC)?
What is the market cap of Bausch Health Companies (BHC)?
